Leerink Partners initiates coverage on Terns Pharmaceuticals (NASDAQ: TERN) with a Outperform rating and a price target of $58.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE